Page last updated: 2024-11-05

4-(dimethylamino)benzoic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

4-(Dimethylamino)benzoic acid, also known as p-dimethylaminobenzoic acid (DMAB), is a white crystalline solid. It is an important intermediate in the synthesis of various pharmaceuticals, dyes, and pigments. It is also used as a UV absorber in sunscreens. DMAB can be synthesized by reacting dimethylamine with p-chlorobenzoic acid in the presence of a base. The compound exhibits biological activity, acting as a weak base and exhibiting antibacterial and antifungal properties. Its unique structure, with the electron-donating dimethylamino group in the para position to the carboxylic acid, makes it an interesting molecule for studies exploring its potential applications in medicine, materials science, and other fields.'

Cross-References

ID SourceID
PubMed CID12092
CHEMBL ID112322
SCHEMBL ID33368
MeSH IDM0097041

Synonyms (53)

Synonym
p-dimethylamino benzoic acid
einecs 210-615-8
nsc 16596
4-dimethylaminobenzoic acid
4-(dimethylamino)benzoic acid
p-n,n-(dimethylamino)benzoic acid
619-84-1
benzoic acid, 4-(dimethylamino)-
p-(dimethylamino)benzoic acid
nsc16596
n,n-dimethyl-4-aminobenzoic acid
benzoic acid, p-(dimethylamino)-
n,n-dimethyl-p-aminobenzoic acid
nsc-16596
p-dimethylaminobenzoic acid
4-(dimethylamino)benzoic acid, 98%
4-(dimethylamino)benzoic acid, 90%, technical grade
inchi=1/c9h11no2/c1-10(2)8-5-3-7(4-6-8)9(11)12/h3-6h,1-2h3,(h,11,12
AC-11462
D0724
DB08748
CHEMBL112322
4-dimethylamino-benzoic acid
AKOS000119548
A833518
4-(n,n-dimethylamino) benzoic acid
STL169142
4-dimethylamino benzoic acid
AE-562/40174962
d1ma908ev0 ,
unii-d1ma908ev0
FT-0618360
4-(dimethylamino)benzoic acid [mi]
4dimethylaminobenzoic acid
4-dimethylaminophenylcarboxylic acid
SCHEMBL33368
DTXSID7060708
W-105063
4-dimethylaminobenzoicacid
CS-W019576
HMS3604D07
mfcd00002537
F2191-0087
GS-3079
SY020179
p-(n,n'-dimethylamino)benzoic acid
Q27097934
bdbm512661
acs.jmedchem.1c00409_st.255
SB76045
EN300-20122
PD004568
Z104476964
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Replicase polyprotein 1abSevere acute respiratory syndrome-related coronavirusKi1.38000.00753.00839.1100AID1805801
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2Ki1.38000.00001.63079.0000AID1805801
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (1)

Processvia Protein(s)Taxonomy
symbiont-mediated perturbation of host ubiquitin-like protein modificationReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K63-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
K48-linked deubiquitinase activityReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome-related coronavirus
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID28693Concentration of the drug in the liver of rat1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID28731Partition coefficient (logD2.0)1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID1060460Inhibition of SIRT2 (unknown origin) at 1.6 mM by fluorescence assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Evaluation of benzoic acid derivatives as sirtuin inhibitors.
AID1060463Inhibition of Sir2p in yeast DMY2844 assessed as growth inhibition after 48 hrs2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Evaluation of benzoic acid derivatives as sirtuin inhibitors.
AID1060461Inhibition of SIRT1 (unknown origin) at 1.6 mM by fluorescence assay2014Bioorganic & medicinal chemistry letters, Jan-01, Volume: 24, Issue:1
Evaluation of benzoic acid derivatives as sirtuin inhibitors.
AID28692Concentration of the drug in the kidney of rat1992Journal of medicinal chemistry, Sep-04, Volume: 35, Issue:18
Energy aspects of oil/water partition leading to the novel hydrophobic parameters for the analysis of quantitative structure-activity relationships.
AID1805801Various Assay from Article 10.1021/acs.jmedchem.1c00409: \\Perspectives on SARS-CoV-2 Main Protease Inhibitors.\\2021Journal of medicinal chemistry, 12-09, Volume: 64, Issue:23
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (10.53)18.7374
1990's2 (10.53)18.2507
2000's7 (36.84)29.6817
2010's7 (36.84)24.3611
2020's1 (5.26)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.99 (24.57)
Research Supply Index3.00 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index32.99 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]